{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:10:15Z","timestamp":1793985015967,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli studi \"Magna Graecia\" di Catanzaro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are promising blood-based biomarkers of neuroaxonal injury and astrocytic activation, relevant in neurodegeneration. We investigated their pre-diagnostic profiles across common neurodegenerative diseases, including Parkinson\u2019s disease (PD), atypical parkinsonian disorders (APD), Alzheimer\u2019s disease (AD), and amyotrophic lateral sclerosis (ALS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Forty-eight thousand five hundred and twenty-four UK Biobank participants with baseline plasma proteomic data for NfL and GFAP were included. Incident diagnoses of PD, APD, AD, and ALS were identified through ICD-10\u2014coded health records, after careful inclusion\/exclusion procedures. Baseline plasma NfL and GFAP concentrations were standardized as\n                      <jats:italic>z<\/jats:italic>\n                      -scores adjusted for relevant covariates. The hazard ratio (HR) for incident neurodegenerative diseases was estimated using Cox regression models adjusted for demographic, clinical, socioeconomic and genetic factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The final sample included 1196 cases (505 PD, 26 APD, 476 AD, 189 ALS) and 44,107 control subjects. In Cox regression models, NfL was associated with higher risk of incident ALS (HR 1.69; 95% CI, 1.58\u20131.80,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), APD (HR 1.51; 95% CI, 1.22\u20131.87,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), AD (HR 1.31; 95% CI, 1.22\u20131.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and PD (HR 1.14; 95% CI, 1.05\u20131.23,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). GFAP was independently associated with incident AD only (HR 1.72; 95% CI, 1.63\u20131.82,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Plasma NfL and GFAP showed distinct pre-diagnostic profiles. NfL was associated with incident diagnosis of several neurodegenerative diseases, while GFAP was specific to AD, reinforcing its role in dementia. These results may help optimize the identification of target populations at risk of neurodegenerative diseases for future neuroprotective treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-025-13498-y","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T10:46:43Z","timestamp":1762685203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: insights from the UK Biobank"],"prefix":"10.1007","volume":"272","author":[{"given":"Jolanda","family":"Buonocore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fratto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Arcuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basilio","family":"Vescio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Calomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza Maria","family":"Cristiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Quattrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2071-2083","authenticated-orcid":false,"given":"Andrea","family":"Quattrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"issue":"3","key":"13498_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","volume":"19","author":"VL Feigin","year":"2020","unstructured":"Feigin VL, Vos T, Nichols E et al (2020) The global burden of neurological disorders: translating evidence into policy. Lancet Neurol 19(3):255\u2013265. https:\/\/doi.org\/10.1016\/S1474-4422(19)30411-9","journal-title":"Lancet Neurol"},{"issue":"6","key":"13498_CR2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27(6):954\u2013963. https:\/\/doi.org\/10.1038\/s41591-021-01382-x","journal-title":"Nat Med"},{"issue":"8","key":"13498_CR3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"issue":"3","key":"13498_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/mds.30112","volume":"40","author":"A Quattrone","year":"2025","unstructured":"Quattrone A, Franzmeier N, Levin J et al (2025) Prospective multicenter evaluation of the MDS \u201cSuggestive of PSP\u201d diagnostic criteria. Mov Disord 40(3):526\u2013536. https:\/\/doi.org\/10.1002\/mds.30112","journal-title":"Mov Disord"},{"issue":"6","key":"13498_CR5","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P et al (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81(6):857\u2013870. https:\/\/doi.org\/10.1002\/ana.24954","journal-title":"Ann Neurol"},{"issue":"8","key":"13498_CR6","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870\u2013881. https:\/\/doi.org\/10.1136\/jnnp-2018-320106","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"13498_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, Teunissen CE, Lehmann S et al (2024) Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nat Rev Neurol 20(5):269\u2013287. https:\/\/doi.org\/10.1038\/s41582-024-00955-x","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"13498_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Janelidze S, Al Khleifat A et al (2021) A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 12(1):3400. https:\/\/doi.org\/10.1038\/s41467-021-23620-z","journal-title":"Nat Commun"},{"issue":"10","key":"13498_CR9","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"7","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S et al (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 7(10):930\u2013937. https:\/\/doi.org\/10.1212\/WNL.0000000000003680","journal-title":"Neurology"},{"issue":"1","key":"13498_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66090-x","volume":"10","author":"C Delaby","year":"2020","unstructured":"Delaby C, Alcolea D, Carmona-Iragui M et al (2020) Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep 10(1):9161. https:\/\/doi.org\/10.1038\/s41598-020-66090-x","journal-title":"Sci Rep"},{"key":"13498_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106978","volume":"123","author":"MG Bianco","year":"2024","unstructured":"Bianco MG, Cristiani CM, Scaramuzzino L et al (2024) Combined blood neurofilament light chain and third ventricle width to differentiate progressive supranuclear palsy from Parkinson\u2019s disease: a machine learning study. Parkinsonism Relat Disord 123:106978. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106978","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"13498_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13051-x","volume":"272","author":"W Kou","year":"2025","unstructured":"Kou W, Li S, Yan R, Zhang J, Wan Z, Feng T (2025) Cerebrospinal fluid and blood neurofilament light chain in Parkinson\u2019s disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis. J Neurol 272(4):311. https:\/\/doi.org\/10.1007\/s00415-025-13051-x","journal-title":"J Neurol"},{"key":"13498_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00768-1","volume":"10","author":"CC Pedersen","year":"2024","unstructured":"Pedersen CC, Ushakova A, Alves G et al (2024) Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson\u2019s disease. NPJ Parkinsons Dis 10:162. https:\/\/doi.org\/10.1038\/s41531-024-00768-1","journal-title":"NPJ Parkinsons Dis"},{"issue":"5","key":"13498_CR14","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA et al (2019) Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92(5):e1007\u2013e1015. https:\/\/doi.org\/10.1212\/WNL.0000000000007032","journal-title":"Neurology"},{"issue":"91","key":"13498_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2016.06.030","volume":"6","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H (2016) Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron 6(91):1\u20133. https:\/\/doi.org\/10.1016\/j.neuron.2016.06.030","journal-title":"Neuron"},{"issue":"9","key":"13498_CR16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","volume":"266","author":"B Olsson","year":"2019","unstructured":"Olsson B, Alberg L, Cullen NC et al (2019) NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 266(9):2129\u20132136. https:\/\/doi.org\/10.1007\/s00415-019-09389-8","journal-title":"J Neurol"},{"issue":"15","key":"13498_CR17","doi-asserted-by":"publisher","first-page":"e1466","DOI":"10.1212\/WNL.0000000000012632","volume":"11","author":"K Bjornevik","year":"2021","unstructured":"Bjornevik K, O\u2019Reilly EJ, Molsberry S et al (2021) Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis. Neurology 11(15):e1466\u2013e1474. https:\/\/doi.org\/10.1212\/WNL.0000000000012632","journal-title":"Neurology"},{"issue":"1","key":"13498_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70071","volume":"17","author":"S De Meyer","year":"2025","unstructured":"De Meyer S, Blujdea ER, Schaeverbeke JM et al (2025) Serum biomarkers as prognostic markers for Alzheimer\u2019s disease in a clinical setting. Alzheimers Dement Diagn Assess Dis Monit 17(1):e70071. https:\/\/doi.org\/10.1002\/dad2.70071","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"13498_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209531","volume":"103","author":"J You","year":"2024","unstructured":"You J, Wang L, Wang Y et al (2024) Prediction of future Parkinson disease using plasma proteins combined with clinical-demographic measures. Neurology 103:e209531. https:\/\/doi.org\/10.1212\/WNL.0000000000209531","journal-title":"Neurology"},{"issue":"2","key":"13498_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische O, Schultz SA, Apel A et al (2019) Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat Med 25(2):277\u2013283. https:\/\/doi.org\/10.1038\/s41591-018-0304-3","journal-title":"Nat Med"},{"issue":"3","key":"13498_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Foschi M, Abu-Rumeileh S et al (2022) Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol 18(3):158\u2013172. https:\/\/doi.org\/10.1038\/s41582-021-00616-3","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"13498_CR22","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/acn3.51652","volume":"9","author":"MM Gonzales","year":"2022","unstructured":"Gonzales MM, Wiedner C, Wang CP et al (2022) A population-based meta-analysis of circulating GFAP for cognition and dementia risk. Ann Clin Transl Neurol 9(10):1574\u20131585. https:\/\/doi.org\/10.1002\/acn3.51652","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"13498_CR23","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1093\/brain\/awae211","volume":"147","author":"DE Peretti","year":"2024","unstructured":"Peretti DE, Boccalini C, Ribaldi F et al (2024) Association of glial fibrillary acid protein, Alzheimer\u2019s disease pathology and cognitive decline. Brain 147(3):4094\u20134104. https:\/\/doi.org\/10.1093\/brain\/awae211","journal-title":"Brain"},{"issue":"11","key":"13498_CR24","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"16","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R et al (2021) Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 16(11):3505\u20133516. https:\/\/doi.org\/10.1093\/brain\/awab223","journal-title":"Brain"},{"issue":"22","key":"13498_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212379","volume":"25","author":"R Arya","year":"2024","unstructured":"Arya R, Haque AKMA, Shakya H et al (2024) Parkinson\u2019s disease: biomarkers for diagnosis and disease progression. Int J Mol Sci 25(22):12379. https:\/\/doi.org\/10.3390\/ijms252212379","journal-title":"Int J Mol Sci"},{"issue":"10","key":"13498_CR26","doi-asserted-by":"publisher","first-page":"6991","DOI":"10.1007\/s00415-024-12647-z","volume":"271","author":"S Katzdobler","year":"2024","unstructured":"Katzdobler S, N\u00fcbling G, Klietz M et al (2024) GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA). J Neurol 271(10):6991\u20136999. https:\/\/doi.org\/10.1007\/s00415-024-12647-z","journal-title":"J Neurol"},{"issue":"4","key":"13498_CR27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mds.29339","volume":"38","author":"SY Huang","year":"2023","unstructured":"Huang SY, Chen SF, Cui M et al (2023) Plasma biomarkers and positron emission tomography tau pathology in progressive supranuclear palsy. Mov Disord 38(4):676\u2013682. https:\/\/doi.org\/10.1002\/mds.29339","journal-title":"Mov Disord"},{"issue":"3","key":"13498_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","volume":"91","author":"C Heller","year":"2020","unstructured":"Heller C, Foiani MS, Moore K et al (2020) Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry 91(3):263\u2013270. https:\/\/doi.org\/10.1136\/jnnp-2019-321954","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13498_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"1","author":"S Meier","year":"2023","unstructured":"Meier S, Willemse EAJ, Schaedelin S et al (2023) Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol 1:287\u2013297. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5250","journal-title":"JAMA Neurol"},{"issue":"2","key":"13498_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14422","volume":"21","author":"GM Bentivenga","year":"2025","unstructured":"Bentivenga GM, Gonzalez-Ortiz F, Baiardi S et al (2025) Clinical value of novel blood-based tau biomarkers in Creutzfeldt-Jakob disease. Alzheimers Dement 21(2):e14422. https:\/\/doi.org\/10.1002\/alz.14422","journal-title":"Alzheimers Dement"},{"issue":"1","key":"13498_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/jnnp-2018-318868","volume":"90","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Weydt P, Steinacker P et al (2019) Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry 90(1):4\u201310. https:\/\/doi.org\/10.1136\/jnnp-2018-318868","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13498_CR32","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"1","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 1:1471\u20131483. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671","journal-title":"JAMA Neurol"},{"issue":"1","key":"13498_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03418-8","volume":"22","author":"X Wang","year":"2024","unstructured":"Wang X, Shi Z, Qiu Y, Sun D, Zhou H (2024) Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank. BMC Med 22(1):192. https:\/\/doi.org\/10.1186\/s12916-024-03418-8","journal-title":"BMC Med"},{"key":"13498_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104970","volume":"101","author":"MS Freedman","year":"2024","unstructured":"Freedman MS, Gnanapavan S, Booth RA et al (2024) Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine 101:104970. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104970","journal-title":"EBioMedicine"},{"issue":"6","key":"13498_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70343","volume":"21","author":"C Delaby","year":"2025","unstructured":"Delaby C, Ladang A, Martinez-Yriarte J et al (2025) Clinical use and reporting of neurofilament quantification in neurological disorders: a global overview. Alzheimers Dement 21(6):e70343. https:\/\/doi.org\/10.1002\/alz.70343","journal-title":"Alzheimers Dement"},{"issue":"8","key":"13498_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/mds.29866","volume":"39","author":"A Quattrone","year":"2024","unstructured":"Quattrone A, Franzmeier N, Huppertz HJ et al (2024) Magnetic resonance imaging measures to track atrophy progression in progressive supranuclear palsy in clinical trials. Mov Disord 39(8):1329\u20131342. https:\/\/doi.org\/10.1002\/mds.29866","journal-title":"Mov Disord"},{"issue":"8","key":"13498_CR37","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(8):512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"13498_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107226","volume":"131","author":"F Abate","year":"2025","unstructured":"Abate F, Di Biasio F, Marchese R et al (2025) Clinical trial eligibility in PSP: population representativeness and potential criteria adjustment based on PSP-NET findings. Parkinsonism Relat Disord 131:107226. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107226","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"13498_CR39","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1007\/s00415-024-12669-7","volume":"271","author":"A Pilotto","year":"2024","unstructured":"Pilotto A, Ashton NJ, Lupini A et al (2024) Plasma NfL, GFAP, amyloid, and p-tau species as prognostic biomarkers in Parkinson\u2019s disease. J Neurol 271(12):7537\u20137546. https:\/\/doi.org\/10.1007\/s00415-024-12669-7","journal-title":"J Neurol"},{"key":"13498_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaf163","author":"C Liguori","year":"2025","unstructured":"Liguori C, Fernandes M, Zatti C et al (2025) Plasma NfL, GFAP and pTau181 in patients with isolated REM sleep behaviour disorder. Sleep. https:\/\/doi.org\/10.1093\/sleep\/zsaf163","journal-title":"Sleep"},{"issue":"2","key":"13498_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mds.30105","volume":"40","author":"RY Lo","year":"2025","unstructured":"Lo RY (2025) To trust or not to trust? ICD-coded diagnosis of Parkinson\u2019s disease. Mov Disord 40(2):181\u2013183. https:\/\/doi.org\/10.1002\/mds.30105","journal-title":"Mov Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13498-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13498-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13498-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:30:39Z","timestamp":1765812639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13498-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["13498"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13498-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no financial or other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"UK Biobank has ethical approval from the North West Multi-Centre Research Ethics Committee. All participants provided written informed consent at recruitment. The study was conducted in accordance with the principles of the Declaration of Helsinki and the UK Biobank Ethics and Governance Framework, ensuring participant confidentiality and adherence to relevant legislation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have approved the manuscript before submission, including the names and order of authors; all gave explicit consent to submit and obtained consent from the responsible authorities at the institute\/organization where the work has been carried out.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"755"}}